Migraine is a neurological conditio

Migraine is a neurological condition that affects approxi-
mately 12% of patients in the United States and
millions worldwide.1
Women are affected dispropor-
tionally, with a 3-fold higher prevalence of migraine disorder.
Prevalence peaks between age 25 and 55 years, affecting the
most productive years of a person’s life.2
Patients experience
varying levels of frequency, severity, and disability associated
with migraine. More frequent and severe cases with significant
impact on patients’ quality of life and daily activities may ben-
efit from headache prophylaxis. Existing prophylaxis therapies
include a variety of options (e.g., beta blockers, antidepressants,
anticonvulsants, onabotulinumtoxinA). At the time of this
study, guidelines, such as those published by the U.S. Headache
Consortium, recommended first-line prophylaxis with pro-
pranolol, timolol, amitriptyline, or divalproex.3
Although some
patients see relief from these therapies, unfavorable side effects
may limit tolerability and thus impact the effectiveness of pro-
phylaxis. Ultimately, patient tolerance is a crucial component
for the success of migraine prophylaxis. A study that explored
the extent to which migraine patients are willing to tolerate
side effects of prophylaxis found that the top reasons why a
prophylactic is deemed intolerable to patients are weight gain,
memory loss, depression, and somnolence.4
These findings can
be readily applied to migraine prophylaxis, where possible side
effects include cognitive effects (topiramate), somnolence (ami-
triptyline and propranolol), and weight gain (divalproex).
Adherence refers to the extent to which a patient follows pre-
scribed directions with respect to timing, dose, and frequency.5
Adherence to chronic therapy is a common issue across many
disease states. Poor adherence (

ผลลัพธ์ (อังกฤษ) 1:

Migraine is a neurological condition that affects approxi-mately 12% of patients in the United States and millions worldwide.1 Women are affected dispropor-tionally, with a 3-fold higher prevalence of migraine disorder. Prevalence peaks between age 25 and 55 years, affecting the most productive years of a person's life.2 Patients experience varying levels of frequency, severity, and disability associated with migraine. More frequent and severe cases with significant impact on patients' quality of life and daily activities may ben-efit from headache prophylaxis. Existing prophylaxis therapies include a variety of options (e.g., beta blockers, antidepressants, anticonvulsants, onabotulinumtoxinA). At the time of this study, guidelines, such as those published by the U.S. Headache Consortium, recommended first-line prophylaxis with pro-pranolol, timolol, amitriptyline, or divalproex.3 Although some patients see relief from these therapies, unfavorable side effects may limit tolerability and thus impact the effectiveness of pro-phylaxis. Ultimately, patient tolerance is a crucial component for the success of migraine prophylaxis. A study that explored the extent to which migraine patients are willing to tolerate side effects of prophylaxis found that the top reasons why a prophylactic is deemed intolerable to patients are weight gain, memory loss, depression, and somnolence.4 These findings can be readily applied to migraine prophylaxis, where possible side effects include cognitive effects (topiramate), somnolence (ami-triptyline and propranolol), and weight gain (divalproex).Adherence refers to the extent to which a patient follows pre-scribed directions with respect to timing, dose, and frequency.5Adherence to chronic therapy is a common issue across many disease states. Poor adherence (<80% of medication taken as prescribed) has been associated with poor outcomes in a num-ber of medication classes.6-

ผลลัพธ์ (อังกฤษ) 2:

Migraine is a neurological condition that affects Approxi-
Mately 12% of Patients in the United States and
Millions Worldwide.1
Women are affected Dispropor-
tionally, with a 3-Fold Higher prevalence of migraine Disorder.
Prevalence Peaks Age between 25 and 55 years,. affecting the
Most Productive years of a person's Life.2
Patients Experience
varying levels of frequency, Severity, and Disability associated
with migraine. More Frequent and severe Cases with significant
Impact on Patients' quality of Life and Daily Activities Ben May
Efit from headache prophylaxis. Prophylaxis existing therapies
include a Variety of options (eg, beta blockers, antidepressants,
anticonvulsants, OnabotulinumtoxinA). At the time of this
Study, guidelines, those Published by the US As such Headache
Consortium, Recommended First-line prophylaxis with pro-
Pranolol, timolol, amitriptyline, or Divalproex.3
Although Some
Patients See relief from these therapies, Unfavorable Side effects
May. Limit Impact tolerability and thus the effectiveness of pro-
Phylaxis. Ultimately, Patient tolerance is a CRUCIAL Component
for the Success of migraine prophylaxis. A Study that explored
the extent to which migraine Patients are willing to tolerate
Side effects of prophylaxis Found that the top Reasons why a
prophylactic is Deemed to Intolerable Patients are weight gain,
memory loss, depression, and Somnolence.4
These findings Can
be Applied readily. to migraine prophylaxis, where possible Side
effects include cognitive effects (topiramate), somnolence (Ami-
Triptyline and propranolol), and weight gain (divalproex).
adherence refers to the extent to which a Patient follows pre-
scribed directions with Respect to timing,. dose, and Frequency.5
Therapy is a common adherence to chronic Issue Across many
States disease. Poor adherence (<80% of Medication taken As
prescribed) has been associated with poor outcomes in a Num-
BER of Medication Classes.6-.

ผลลัพธ์ (อังกฤษ) 3:

Migraine is a neurological condition that affects approxi -
mately 12% of patients in the United States millions worldwide.1 and

. Women are affected dispropor -
tionally with a, 3-fold higher prevalence of migraine disorder.
Prevalence peaks between. Age 25 and, 55 years affecting the
most productive years of a person 's life.2

Patients experience varying levels, of frequency. Severity.And disability associated
with migraine. More frequent and severe cases with significant
impact on patients quality. ' Of life and daily activities may Ben -
efit from headache prophylaxis. Existing prophylaxis therapies
include a variety. Of options (e.g. Beta blockers,,,, antidepressants
anticonvulsants onabotulinumtoxinA). At the time of this
study guidelines,,Such as those published by the U.S. Headache
Consortium recommended first-line, prophylaxis with pro -
pranolol timolol,,, Amitriptyline or divalproex.3

, Although some patients see relief from, these therapies unfavorable side effects
may limit. Tolerability and thus impact the effectiveness of pro -
phylaxis. Ultimately patient tolerance, is a crucial component
.For the success of migraine prophylaxis. A study that explored
the extent to which migraine patients are willing to tolerate.
side effects of prophylaxis found that the top reasons why a
prophylactic is deemed intolerable to patients are weight. Gain
memory,,, loss depression and somnolence.4
These findings can
be readily applied to, migraine prophylaxis where. Possible side
.Effects include cognitive effects (topiramate), somnolence (AMI -
triptyline and propranolol), and weight gain (divalproex).
Adherence. Refers to the extent to which a patient follows pre -
scribed directions with respect to timing dose and frequency.5
Adherence,,, To chronic therapy is a common issue across many
disease states. Poor adherence (< 80% of medication taken as
.Prescribed) has been associated with poor outcomes in a num -
BER of medication classes.6 -.